Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of AMGN have gained 13.5%, while those of BMY have gained 13.9%. The industry has ...

Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio ...

Barclays raised the firm’s price target on Cytokinetics (CYTK) to $87 from $82 and keeps an Overweight rating on the shares. The firm says Myqorzo received FDA approval in obstructive hypertrophic ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...